Applications

ABCDEFGHIJKLM
NOPQRSTUVWXYZALL

Measuring Hematopoietic Cell Proliferation (CFU/CFC Assays)

The ability to model human hematopoietic cell differentiation is critical for many areas of biomedical research including drug-induced hematopoietic cell toxicity, bone marrow transplant tolerance, cancer immunother

Learn More
Print
Description Available Resources

Measuring Hematopoietic Cell Proliferation (CFU/CFC Assays)

Discovery, Toxicity

The ability to model human hematopoietic cell differentiation is critical for many areas of biomedical research including drug-induced hematopoietic cell toxicity, bone marrow transplant tolerance, cancer immunotherapy, and autoimmune disorders. CDI’s hematopoietic progenitor cells offer access to commercial quantities of highly pure hematopoietic cells, providing reproducible results for these and other research and therapeutic applications.

High-throughput Screening

Drug failure in the clinic is most often attributed to either unforeseen toxicity or a lack of demonstrated efficacy.

Learn More
Print
Description Available Resources

High-throughput Screening

Discovery

Drug failure in the clinic is most often attributed to either unforeseen toxicity or a lack of demonstrated efficacy. Thus, predictive in vitro models that more accurately reflect in vivo disease states can inform the preclinical processes of drug discovery and development ensuring higher success rate in the eventual clinical setting. CDI’s iCell and MyCell products offer a wide range of innate, engineered, and induced disease models for screening, hit-to-lead, and lead optimization efforts. The cells are amenable to gene modulation and culture in high-density multiwell plates. iCell and MyCell products have been used in high-throughput screens across various disease areas including infectious disease, neurological disorders, diabetes, and cardiomyopathies.